Revenue
YoY n/m$0 FY25— Q3 '26
FY22FY23FY24FY25
Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
PRAX
$328.13+1.04%
as of close, Nov 13, 2026
☾ AH $328.13 +1.04%
Praxis Precision Medicines Inc.Stock · HealthcareRussell 2000 · 0.3% of IWMNasdaq Composite · 0.02% of ONEQUS Stock Market · 0.01% of VTIRussell 3000 · 0.01% of IWV
Head-to-head:Compare with ABVX or any ticker →
PRAX financial statements
The full income statement, balance sheet, and cash-flow statement for Praxis Precision Medicines Inc. (PRAX), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Financial overview#
Operating income
5Y n/m5Y n/mYoY n/m−$406.7M TTM−$106.9M Q3 '26
FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Net income
5Y n/m5Y n/mYoY n/m−$359.4M TTM−$94.2M Q3 '26
FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
EPS (diluted)
5Y n/m5Y n/mYoY n/m−$12.76 TTM−$3.23 Q3 '26
FY20FY21FY22FY23FY24FY25TTM
Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Operating cash flow
5Y n/m5Y n/mYoY n/m−$321.8M TTM−$81.7M Q3 '26
FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Capital expenditure
5Y n/m5Y n/mYoY n/m$1.9M TTM— Q3 '26
FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Free cash flow
5Y n/m5Y n/mYoY n/m−$323.6M TTM— Q3 '26
FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares (diluted)
5Y +3671.7%5Y +3671.7%YoY +32.8%28.2M TTM29.2M Q3 '26
FY20FY21FY22FY23FY24FY25TTM
Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares outstanding (point-in-time)
2024-09 18.6M2024-12 20.2M2025-03 20.4M2025-06 21.0M2025-09 25.0M2025-12 25.2M2026-03 27.9M2026-06 27.9M2026-09 28.0M+50.0% over 8 periods
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
PeriodRangeOrderChangeFiguresAs-reported fiscal years.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Revenue | 0.00-100.0% | 8.55M+249.5% | 2.45M | 0.00 | — | |
| 326M+56.3% | 209M+62.0% | 129M-40.1% | 215M+28.5% | 167M+170.0% | ||
| Research & development | 267M+75.3% | 152M+75.7% | 86.8M-44.0% | 155M+28.9% | 120M+167.4% | |
| Selling, general & administrative | 59.1M+4.9% | 56.3M+33.9% | 42.1M-29.8% | 59.9M+27.3% | 47.1M+177.0% | |
| General & administrative | 59.1M+4.9% | 56.3M+33.9% | 42.1M-29.8% | 59.9M+27.3% | 47.1M+177.0% | |
| Operating income | -326M-63.0% | -200M-58.4% | -126M+41.2% | -215M-28.5% | -167M-170.0% | |
| Other non-operating income | 22.9M+32.2% | 17.3M+460.3% | 3.10M+223.5% | 957K+253.1% | 271K+93.6% | |
| Pre-tax income | -303M-65.7% | -183M-48.6% | -123M | — | -167M-170.2% | |
| Income tax | 471K | — | — | — | 0.00+100.0% | |
| -303M-65.9% | -183M-48.3% | -123M+42.4% | -214M-28.1% | -167M-170.2% | ||
| Net income to common | -303M-65.9% | -183M-48.3% | -123M+42.4% | -214M-28.1% | -167M-137.6% | |
| -$13.48-32.0% | -$10.21+45.4% | -$18.69+73.2% | -$69.65-17.9% | -$59.10+49.9% | ||
| EPS (basic) | -$13.48-32.0% | -$10.21+45.4% | -$18.69+73.2% | -$69.65-17.9% | -$59.10+49.9% | |
| Weighted-avg shares (basic) | 22.5M+25.7% | 17.9M+171.5% | 6.59M+114.6% | 3.07M+8.6% | 2.83M+374.3% | |
| Weighted-avg shares (diluted) | 22.5M+25.7% | 17.9M+171.5% | 6.59M+114.6% | 3.07M+8.6% | 2.83M+374.3% | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 611M+51.1% | 404M+376.4% | 84.9M-23.4% | 111M-61.4% | 287M-4.9% | ||
| Cash & equivalents | 357M+65.9% | 215M+164.9% | 81.3M+31.9% | 61.6M-55.6% | 139M-53.2% | |
| Short-term investments | 242M+36.6% | 177M | — | — | — | |
| Cash & short-term investments | 926M+97.3% | 470M | 0.00 | — | 276M | |
| Prepaid expenses | 11.6M-1.9% | 11.8M+229.7% | 3.58M-65.4% | 10.4M-10.0% | 11.5M+101.1% | |
| 938M+94.1% | 483M+449.3% | 87.9M-23.6% | 115M-60.7% | 293M-3.4% | ||
| Property, plant & equipment | 147K-36.1% | 230K-60.9% | 588K-39.4% | 971K-20.0% | 1.21M+1379.3% | |
| Operating lease right-of-use | 92.0K-91.9% | 1.13M-45.2% | 2.06M-28.9% | 2.90M-20.6% | 3.65M+384.5% | |
| Intangible assets | 0.00 | — | — | — | — | |
| Long-term investments | 327M+324.6% | 77.0M | — | — | — | |
| Other non-current assets | 0.00-100.0% | 416K+0.0% | 416K+0.0% | 416K-11.9% | 472K+3046.7% | |
| 59.8M+59.2% | 37.5M+138.4% | 15.7M-54.1% | 34.3M-10.6% | 38.4M+144.5% | ||
| Accounts payable | 24.6M+96.6% | 12.5M+115.4% | 5.82M-60.4% | 14.7M+36.1% | 10.8M+163.7% | |
| Accrued liabilities | 35.0M+47.4% | 23.8M+220.4% | 7.42M-53.2% | 15.8M-41.0% | 26.8M+147.0% | |
| Deferred revenue | — | 0.00-100.0% | 1.39M-50.6% | 2.82M | 0.00 | |
| Current lease liability | 110K-91.3% | 1.26M+11.8% | 1.13M+12.0% | 1.00M+24.1% | 810K+6.2% | |
| 59.8M+58.7% | 37.7M+106.0% | 18.3M-53.2% | 39.0M-6.9% | 41.9M+166.8% | ||
| Deferred revenue (non-current) | — | 0.00-100.0% | 1.16M-46.8% | 2.18M | 0.00 | |
| Non-current lease liability | 0.00-100.0% | 110K-92.0% | 1.37M-45.1% | 2.50M-28.7% | 3.50M | |
| Operating lease liability (total) | 110K-92.0% | 1.37M-45.1% | 2.50M-28.7% | 3.50M-18.8% | 4.31M+465.0% | |
| 878M+97.1% | 445M+539.4% | 69.7M-8.5% | 76.1M-69.7% | 251M-12.7% | ||
| Preferred stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock | 15.0K+7.1% | 14.0K+7.7% | 13.0K+160.0% | 5.00K+0.0% | 5.00K+25.0% | |
| Additional paid-in capital | 2.02B+57.4% | 1.28B+77.1% | 724M+19.2% | 607M+6.9% | 568M+29.9% | |
| Retained earnings | -1.14B-36.2% | -837M-28.0% | -654M-23.2% | -531M-67.6% | -317M-111.7% | |
| Accumulated other comprehensive income | 563K-13.9% | 654K | 0.00+100.0% | -173K+1.7% | -176K | |
| Total equity incl. non-controlling | 878M+97.1% | 445M+539.4% | 69.7M-8.5% | 76.1M-69.7% | 251M-12.7% | |
| Total liabilities & equity | 938M+94.1% | 483M+449.3% | 87.9M-23.6% | 115M-60.7% | 293M-3.4% | |
| Common shares issued | 25.2M+29.7% | 19.4M+120.9% | 8.79M+167.1% | 3.29M+9.0% | 3.02M+18.4% | |
| Common shares outstanding | 25.2M+29.7% | 19.4M+120.9% | 8.79M+167.1% | 3.29M+9.0% | 3.02M+18.4% | |
| Shares outstanding (cover) | 27.9M+38.1% | 20.2M+52.3% | 13.2M+279.0% | 3.49M+15.2% | 3.03M+17.9% | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| -249M-89.0% | -132M-18.6% | -111M+39.9% | -185M-48.6% | -125M-136.7% | ||
| Depreciation & amortization | 140K-60.9% | 358K-17.1% | 432K+3.1% | 419K+130.2% | 182K+264.0% | |
| Share-based compensation | 33.9M-17.9% | 41.4M+66.4% | 24.9M-13.1% | 28.6M+26.0% | 22.7M+335.5% | |
| Change in payables | 12.1M+80.2% | 6.71M+175.8% | -8.86M-327.5% | 3.89M-46.4% | 7.27M+657.0% | |
| Other operating activities | 0.00-100.0% | 2.00K | 0.00-100.0% | 56.0K+236.6% | -41.0K-920.0% | |
| -311M-25.2% | -248M-738.0% | 39.0M-59.8% | 96.9M+169.0% | -141M | ||
| Capital expenditure | 56.0K | 0.00-100.0% | 50.0K-88.7% | 444K-57.7% | 1.05M | |
| Free cash flow | -249M-89.1% | -132M-18.5% | -111M+40.1% | -185M-47.7% | -126M-138.7% | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 702M+36.5% | 514M+459.8% | 91.9M+777.9% | 10.5M-90.3% | 108M-64.7% | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock issued | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 98.4M | |
| Common stock repurchased | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net change in cash | 142M+5.9% | 134M+581.1% | 19.7M+125.3% | -77.7M+50.7% | -157M-162.5% | |
| Income taxes paid | 224K | — | — | — | — | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 7.43B+378.6% | 1.55B+712.7% | 191M+70.3% | 112M-87.4% | 892M-58.0% | |
| P/S | — | 181.4×+83.6% | 98.8× | — | — | |
| P/B | 8.5×+142.8% | 3.5×+58.3% | 2.2×+106.4% | 1.1×-70.0% | 3.6×-51.8% | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
CEO pay#
As charts →| Fiscal year | CEO | Total, as reported | Actually paid | Other executives, average | $100 in the stock | $100 in peers |
|---|---|---|---|---|---|---|
| FY2025 | Marcio Souza | $8.7M | $55.5M | $3M | $35.71 | $124.75 |
| FY2024 | — | $13.4M | $20.6M | $4M | $9.33 | $93.49 |
| FY2023 | — | $2.1M | $1.4M | $933.5K | $2.70 | $94.03 |
| FY2022 | — | $6M | −$17.6M | $2.5M | $4.33 | $89.90 |
| FY2021 | — | $10.9M | −$62.2M | $4.1M | $35.81 | $100.02 |
From the pay-versus-performance table of each proxy statement (DEF 14A), the newest that states the year. “Actually paid” values stock awards at the year’s closing price, so it falls when the stock does. A year two chief executives shared lists each one’s pay, as reported / actually paid, and the totals are both. $100 in the stock and in the peer group the proxy names are the newest proxy’s, from the start of its first year.
About this data
Source: PRAX’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all PRAX filings on SEC EDGAR → Not investment advice.
Head-to-head:Compare with ABVX or any ticker →